Related Experiment Videos
Monoclonal antibodies with cytotoxic reactivities against human gliomas
A Nanda1, B Liwnicz, B F Atkinson
1Department of Neurosurgery, Hahnemann University, Philadelphia, Pennsylvania.
Abstract:
Monoclonal antibodies (MAb's) reactive with human malignant glioma cells were derived from mice inoculated with cells from fresh glioma tissue. Seven MAb's were selected for study based on their high-level binding in immunoperoxidase and immunofluorescence assay to most of the glioma tissues derived from various patients and based on the absence of binding to normal bone marrow cells. Four of the seven MAb's did not bind to any of the four normal brain tissues tested, whereas three MAb's bound to one or two of these tissues. Two MAb's bound to the surfaces of cultured glioma cells in radioimmunoassay. One of these MAb's (AS-AY1, immunoglobulin (Ig)(G1) lysed cultured glioma cells with human lymphocytes or murine macrophages as effector cells; the other MAb (AS-AY2, IgM) was reactive in complement-dependent cytotoxicity assay. These two MAb's therefore seem especially promising reagents in approaches to immunotherapy of human malignant glioma.
Insights
Researchers developed seven monoclonal antibodies (MAbs) targeting malignant glioma cells. Two MAbs show promise for immunotherapy by effectively targeting glioma cells and demonstrating cytotoxicity.
Area of Science:
- Immunology
- Oncology
- Neuroscience
Background:
- Malignant gliomas are aggressive brain tumors with limited treatment options.
- Development of targeted therapies, such as monoclonal antibodies (MAbs), is crucial for improving patient outcomes.
- Identifying specific tumor antigens on glioma cells is a key step in developing effective immunotherapies.
Purpose of the Study:
- To derive and characterize monoclonal antibodies (MAbs) reactive with human malignant glioma cells.
- To evaluate the specificity and binding affinity of selected MAbs to glioma tissues and normal cells.
- To assess the potential of these MAbs in mediating direct killing of glioma cells for immunotherapy.
Main Methods:
- Generation of MAbs in mice immunized with fresh human glioma tissue.
- Screening of MAbs using immunoperoxidase and immunofluorescence assays on glioma and normal tissues.
- Radioimmunoassay (RIA) to confirm surface binding to cultured glioma cells.
- Assessment of MAb-mediated cytotoxicity using human lymphocytes or murine macrophages (effector cells) and complement-dependent cytotoxicity (CDC) assays.
Main Results:
- Seven MAbs were selected based on high binding to most glioma tissues and no binding to normal bone marrow cells.
- Four MAbs showed no binding to normal brain tissues, while three bound to one or two normal brain tissues.
- Two MAbs (AS-AY1 and AS-AY2) demonstrated binding to the surface of cultured glioma cells.
- MAb AS-AY1 (IgG1) lysed cultured glioma cells with effector cells.
- MAb AS-AY2 (IgM) was reactive in complement-dependent cytotoxicity assays.
Conclusions:
- Monoclonal antibodies targeting human malignant glioma cells have been successfully derived.
- Two MAbs, AS-AY1 and AS-AY2, exhibit promising reactivity and cytotoxic potential against glioma cells.
- These MAbs represent potential candidates for the development of novel immunotherapies for malignant glioma.